Latest Headlines

Latest Headlines

NIAID funds Soligenix with $2.7M in ricin vaccine effort

If this week's collaborations are any indication, the U.S. government isn't taking bioterror threats lightly. Just days after a separate agency struck an anthrax vaccine partnership potentially worth $143.5 million, the National Institute for Allergy and Infectious Diseases (NIAID) on Wednesday signed the first contract option in its partnership with Princeton, NJ-based Soligenix to forward work on the company's ricin vaccine candidate RiVax.

Army researchers start ricin vaccine trial

U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) is starting a Phase I trial of a new vaccine to protect against ricin. The trial will examine the safety of the vaccine and its